U.S. drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further investments planned, CEO Robert Bradway said at the inauguration of the site on Monday.

The site is expected to accelerate Amgen’s digital capabilities through artificial intelligence and data science to further advance its pipeline of medicines, while creating significant opportunities for local talent.

Amgen invests $200M in India's tech center to leverage AI for drug development. The U.S. FDA seeks to rehire 300 staff including those for Neuralink. Saudi Arabia reaffirms $500M towards polio eradication.

Amgen (NASDAQ: AMGN) is investing $200 million in its new technology and innovation center in Hyderabad, India, to enhance AI and data-driven drug development. CEO Robert Bradway, speaking at the sites inauguration,

Global biotech leader Amgen opened its $200 million technology and innovation centre in Hyderabad, a facility that will help the U.S. firm ramp up digital capabilities, open more opportunities for the talent pool of the region and build on the city’s position as an emerging hub for global capability centres (GCC).

U.S. drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further investments planned, Chief Executive Officer Robert Bradway said at the inauguration of the site on Monday.

HYDERABAD: US-based biopharma giant on Monday opened its new technology and innovation centre in Hyderabad with its CEO Robert Bradway announcing a $200 million (approx Rs 1600 crore) investment commitment in the facility through 2025 with additional investments planned in future years.